Document is current

Article History

Received: 24 June 2025

Accepted: 14 November 2025

First Online: 3 December 2025

Change Date: 20 February 2026

Change Type: Update

Change Details: In this article the affiliation details for Federico Cappuzzo were incorrectly given as 'Istituto Nazionale Tumori Regina Elena, Rome, Italy' but should have been 'Istituto Nazionale Tumori IRCCS Regina Elena, Rome, Italy'. The original article has been updated.

Competing interests

: M.A.S. declares grants or contracts from AstraZeneca, BeOne, Enliven, Genentech, and Lilly; consulting fees from BMS, Lilly, Spectrum, and Summit; payment or honoraria from AstraZeneca, Guardant, Janssen, Jazz, and Merck/MSD; and participation on a data safety monitoring board or advisory board for BMS and Summit. M.R. declares consulting fees from Amgen, AstraZeneca, Beigene, Boehringer-Ingelheim, BMS, Daiichi-Sankyo, GSK, Janssen, Lilly, Merck/MSD, Mirati, Novartis, Pfizer, Regeneron, Roche, and Sanofi; payment or honoraria from Amgen, AstraZeneca, Beigene, Boehringer-Ingelheim, BMS, Daiichi-Sankyo, GSK, Janssen, Lilly, Merck/MSD, Mirati, Novartis, Pfizer, Regeneron, Roche, and Sanofi; support for attending meetings and/or travel from Amgen, AstraZeneca, Beigene, Boehringer-Ingelheim, and BMS; and participation on a data safety monitoring board or advisory board for Daiichi-Sankyo and Sanofi. F.C. declares grants or contracts from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, BMS, Galecto, Illumina, Lilly, Merck/MSD, Mirati, Novocure, OSE, Pfizer, Pharmamar, Regeneron, Roche, Sanofi, Summit Therapeutics, Takeda, and Thermofisher; consulting fees from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, BMS, Galecto, Illumina, Lilly, Merck/MSD, Mirati, Novocure, OSE, Pfizer, Pharmamar, Regeneron, Roche, Sanofi, Summit Therapeutics, Takeda, and Thermofisher; payment or honoraria from AbbVie, Amgen, AstraZeneca, Bayer, Beigene, BMS, Galecto, Illumina, Lilly, Merck/MSD, Mirati, Novocure, OSE, Pfizer, Pharmamar, Regeneron, Roche, Sanofi, Summit Therapeutics, Takeda, and Thermofisher; and participation on a data safety monitoring board or advisory board for AbbVie, Amgen, AstraZeneca, Bayer, Beigene, BMS, Galecto, Illumina, Lilly, Merck/MSD, Mirati, Novocure, OSE, Pfizer, Pharmamar, Regeneron, Roche, Sanofi, Summit Therapeutics, Takeda, and Thermofisher. F.B. declares participation on a data safety monitoring board or advisory board for AbbVie, ACEA, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Eli Lilly Oncology, Eisai, F. Hoffmann–La Roche Ltd, Genentech, Ignyta, Innate Pharma, Ipsen, Loxo, MedImmune, Merck/MSD, Novartis, Pfizer, Pierre Fabre, Sanofi-Aventis, Summit Therapeutics, and Takeda; payments made to their institution. R.M.J. declares receiving personal fees and advisory board participation with Mirati Therapeutics, Inc. E.F. declares consulting fees from Genentech. D.S.S. declares royalties or licenses from UTSW Medical Center, stock in BeOne Medicines, and was an employee of Genentech at the relevant time of this study. T.L., H.H., S.M., A.Q., A.A., X.G., H.K., J.M.G., M.B., M.X.H., Y.W., M.K.S., and B.Y.N. declare they are employees of Genentech/Roche and hold Roche stock.